Efficacy, safety, and cost of new anticancer drugs
- PMID: 12153927
- PMCID: PMC1123779
- DOI: 10.1136/bmj.325.7358.269
Efficacy, safety, and cost of new anticancer drugs
Figures
Comment in
-
Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.BMJ. 2002 Nov 30;325(7375):1302; author reply 1302. doi: 10.1136/bmj.325.7375.1302/a. BMJ. 2002. PMID: 12458261 Free PMC article. No abstract available.
-
Efficacy, safety, and cost of new anticancer drugs. Price needs to be evaluated against effectiveness.BMJ. 2002 Nov 30;325(7375):1302; author reply 1302. BMJ. 2002. PMID: 12463189 No abstract available.
References
-
- Quinn MJ, Babb PJ, Brock A, Kirby EA, Jones J. Cancer trends in England and Wales, 1950-1999. London: Stationery Office; 2001. pp. 206–207. . (Studies on medical and population subjects No 66.)
-
- Levi F, Lucchini F, Negri E, La Vecchia C. The decline in cancer mortality in the European Union, 1988-1996. Eur J Cancer. 2000;36:1965–1968. - PubMed
-
- Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467. - PubMed
-
- Early breast cancer trialists' collaborative group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998;352:930–942. - PubMed
-
- Berrino F, Gatta G, Chessa E, Valente F, Capocaccia R the Eurocare Working Group. Introduction: the Eurocare II study. Eur J Cancer. 1998;34:2139–2153. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources